November 2012

Beijig Percans Oncology Co.Ltd. was registered and established in Beijing

December 2013

The clinical trial named “The study on individualized drug screening using the patient's own transplanted tumor models” was carried out.

January 2015

Equity investment of RMB 25 million from Legend Capital and Legend Star was obtained in series-A financing

September 2015

The company settled in PKUcare Industrial Park, and built 800m2 standard SPF animal facility and laboratory

August 2016

i-Chemo® novel technology was officially released for the first time

January 2017

The clinical study named “The study on individualized drug screening using the patient's micro-tumor models” was carried out

February 2017

Investment of RMB 50 million from Fortune United/Partners was obtained in series-B financing

April 2017

The clinical study named “The study on individualized screening of chemotherapy drugs for patients with advanced colorectal cancer of potential surgical transformation using Conditional Reprogrammed Primary Tumor Cell Library” was carried out

August 2017

The i-CR® tumor primary cell culture in vitro detection system and related experimental kits were launched

January 2018

Cothera Bioscience,Inc. was established and obtained an angel investment of USD 5.5 million

November 2018

Percans Oncology passed national high-tech enterprise certification

May 2019

The reorganization between Cothera Bioscience and Percans Oncology was completed. The company possesses an international team and an advanced basic research platform. Drugs under research are in phase I/II clinical stage

October 2020

Percans Oncology passed Zhongguancun Golden Seed Enterprise Certification

December 2020

Cothera Bioscience completed the series-B financing, and obtained USD 30 million of investment